The estimated Net Worth of Nancy Valente is at least $1.6 Million dollars as of 2 May 2024. Nancy Valente owns over 4,745 units of Myovant Sciences Ltd stock worth over $1,487,003 and over the last 3 years Nancy sold MYOV stock worth over $111,887.
Nancy has made over 1 trades of the Myovant Sciences Ltd stock since 2024, according to the Form 4 filled with the SEC. Most recently Nancy sold 4,745 units of MYOV stock worth $111,887 on 2 May 2024.
The largest trade Nancy's ever made was selling 4,745 units of Myovant Sciences Ltd stock on 2 May 2024 worth over $111,887. On average, Nancy trades about 678 units every 0 days since 2021. As of 2 May 2024 Nancy still owns at least 55,115 units of Myovant Sciences Ltd stock.
You can see the complete history of Nancy Valente stock trades at the bottom of the page.
Nancy's mailing address filed with the SEC is C/O XENCOR, INC., 465 N HALSTEAD STREET, SUITE 200, PASADENA, CA, 91107.
Over the last 8 years, insiders at Myovant Sciences Ltd have traded over $5,780,890 worth of Myovant Sciences Ltd stock and bought 96,585,963 units worth $2,001,605,371 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ..., and Andrew Lo. On average, Myovant Sciences Ltd executives and independent directors trade stock every 15 days with the average trade being worth of $25,106,967. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 10 March 2023, trading 51,599,200 units of MYOV stock currently worth $1,393,178,400.
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.
Myovant Sciences Ltd executives and other stock owners filed with the SEC include: